Arbor Rapha Capital Bioholdings Corp. I

Arbor Rapha Capital Bioholdings Corp. I

ARCKU
Arbor Rapha Capital Bioholdings Corp. IUS flagNASDAQ Global Market
12.00
USD
- -
- -
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChat
CEO
Ivan Paul Kaufman
Sector
Financial Services
Industry
Shell Companies
Address
333 Earle Ovington Blvd Uniondale NY United States of America 11553
Business
Arbor Rapha Capital Bioholdings Corp. I (NASDAQ: ARCKU) operates as a blank check company whose primary purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses in the biopharmaceutical sector; it targets disruptive technologies with potential to transform healthcare and improve patient lives. The company offers no current products or services beyond its SPAC structure, including units comprising one share of Class A common stock and one-third of a redeemable warrant exercisable at $11.50 per share to purchase additional Class A common shares. Founded in 2021 by Arbor Rapha Capital, LLC and headquartered in Uniondale, New York, it draws on management expertise from sponsor affiliates Rapha Capital Management, LLC and RNA Advisors, LLC, with a board including Chairman Ivan Kaufman, Kevin Slawin, M.D., Cyrus Walker, Avery Modlin and Ralph Mack. The company completed its initial public offering in November 2021, raising $172.5 million through 17.25 million units at $10.00 each, including the full exercise of underwriters' over-allotment option by Cantor Fitzgerald & Co.; as of late 2025, its shares remain listed on Nasdaq amid a trading halt pending additional disclosure, with no business combination announced to date.